Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tisagenlecleucel - Novartis/University of Pennsylvania

Next Previous
Drug Profile

Tisagenlecleucel - Novartis/University of Pennsylvania

Alternative Names: Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; Anti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Novartis; Anti-CD19-chimeric-antigen-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-chimeric-immune-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-CIR-retroviral-vector-transduced-autologous-T-cell-therapy-Novartis; CART-019; CART-19; CART-19 cells; CART-19-cells-Novartis; CART19-Novartis; CD19-targeted-chimeric-antigen-receptor-immunotherapy-Novartis; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL-019; Kimria; Kymriah; LG-740; tisagenlecleucel; tisagenlecleucel-T

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor B-cell lymphoblastic leukaemia-lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II Multiple myeloma
  • No development reported B-cell lymphoma; B-cell prolymphocytic leukaemia; Breast cancer; Lymphoma; Mantle-cell lymphoma; Mesothelioma; Ovarian cancer; Pancreatic cancer
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 28 May 2025 Novartis Pharmaceuticals completes a phase II ELARA trial in Follicular lymphoma (Second-line therapy or greater) in United Kingdom, Italy, Germany, Netherlands, Spain, France, Austria, Belgium, Norway, Japan, Australia and USA (IV, Infusion) (EudraCT2017-004385-94) (NCT03568461)
  • 02 Jan 2025 3882226- Real world data hence not covered
  • 07 Dec 2024 Clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In neonates) (Parenteral) prior to December 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top